Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCAR-001 + STK-009 in Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330Phase 1Active, not recruiting
- Sponsor
- Synthekine
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYNCAR-001 and STK-009 in systemic lupus erythematosus (SLE), lupus nephritis (LN) and systemic sclerosis (SSc), sponsored by Synthekine. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 96 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
SYNCAR-001STK-009
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06544330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544330.